# Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

> **NCT05697640** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 104 (estimated)

## Conditions studied

- Post-COVID ME/CFS

## Interventions

- **DRUG:** Vericiguat Oral Tablet

## Key facts

- **NCT ID:** NCT05697640
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-22
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05697640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05697640, "Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05697640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*